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ABSTRACT : There were reported some kinds of anticancer drugs which have 
immunopotentiating effect. In this study, we demonstrated the i.p injection of CDDP 
which enhance the macrophage-mediated cytostatic effect in mice. Flow cytometry 
has been used to study the influence of CDDP-activated macrophages on the cell 
cycle of Meth-A cells, and the biochemical changes of the CDDP-activated macro-
phages were analysed. Macrophages harvested four days later from mice treated 
with i.p injection of CDDP 0.3~4 mg/kg showed a dose-dependent effect to both 
EL-4 and Mrth-A cells. The activation was mainly seen in the plastic adhesive cells 
and was diminished by treating with carrageenan. In vivo Winn assay, CDDP-acti-
vated macrophages showed a significant inhibitory effect to the proliferation of 
Meth-A cells for at least 15 days. 
 The survival time was elongated when the tumor-bearing mice were treated with 
i.p injection of CDDP. However, the elongative effect was diminished by the pretreat-
ment of carragenan. On the other hand, Flow cytometry analysis using Propidium 
Iodide staining was designed to study the mechanism of the tumor cell inhibitory 
effect by CDDP and CDDP-activated macrophages. Changes of cell elements such as 
RNA, protein, and mitochondria were evaluated by A.O, FITC and Rhodamin 123 
staining technique respectively. 
 CDDP does enhance the antitumor effect of the peritoneal macrophages of mice. 
Using the Flow cytometry analysis we have been able to demonstrate that in cont-
rast to CDDP which accumulate the Meth-A cells in the G2M phase of the cell cycle, 
CDDP-activated macrophages appeared to have a different influence more restricted 
to the G1/S block of the cycle. 
 CDDP-activated macrophages resembled to OK-432-activated macrophages, show-
ing an increase of RNA, protein synthesis and an enhancement of the mitochondria 
menbrane potential.
       INTRODUCTION 
 Macrophage inflammatory responses which 
resulted in tumor lysis or proliferative inhibi-
tion seen-is to be one of the central importances,1) 
especially in cases involving solid tumors.
Tumors heavily infiltrated with macrophages 
are less likely to metastasize and show a good 
prognosis.2) 3) 4) 5) 
 On the other hand, patients and animals with 
neoplasms, generally defective monocyte/macro-
phage function has been demonstrated.h) 7) 8) 9) 
Whether these functions are defective before the
onset of neoplasia or become defective as a re-
sult of the tumor formation is not known. 
However, it is reasonable to use some regimens 
that can destroy the tumor cells and stimulate 
the host's natural immune processes in regards 
of the cancer therapy. 
 Anticancer chemotherapy was widely used in 
the bed-side and clinic for cancer patients as a 
post-operative adjuvant therapy or in the cases 
of progressive pleural /peritoneal carcinoma-
tosa. However, the influence to the host's im-
munologic effector cells was not yet well known. 
 In general, chemotherapeutic agents have tra-
ditionally,been thought to cause depression of 
                  10) 11) 12) 13) but it has immuneresponsiveness, 
become clear that some kinds of chemothera-
peutic agents e.g Cyclophosphamide,14 )Adria-
mycin,14)15)16) Mitomycin C, 17) and Bleomycin18) 
act to the host immune effector cells as an im-
munopotentiating factor. 
 Lichtensteinl9) demonstrated the enhancement 
of natural killer cytolysis of peritoneal and 
spleen cells of the mice by CDDP, Kleinerman 
et al .20) reported the enhancement of cytotoxi-
city of human peripheral blood monocyte by 
CDDP. In this study, in respect to cytostatic 
effect, we do the further investigation in vitro 
and in vivo on mice to evaluate the influence 
of CDDP on peritoneal macrophages. Also we 
analysed the kinetics of the target cell cycle 
and the biochemical changes of the effector cell 
by using the Flow cytometry. CDDP activates 
macrophages and inhibits the growth of tumor 
cells, suggesting that the drug may exert an 
effect similar to Biological Response Modifier 
(BRM) in addition to its known direct toxici-
ty, and may have potential clinical usefulness 
in the design of immunotherapeutic trials for 
certain types of cancer. 
   MATERIALS AND METHODS 
1) Animals, tumor cells, chemicals and reagents 
 C 57 BL/6 and BALB/C mice were obtained 
from Chales River Breed Laboratory, Japan. 
All animals were male, eight to 12 weeks old 
and weighed approximately 25 to 30 g. EL-4, a 
T-cell lymphoma of the C 57BL /6 mouse and 
Meth-A, a fibrosarcoma of BALB /C mouse 
were maintained in RPMI 1640 containing 10%
FCS when used as target cells in vitro cytosta-
sis assay and were maintained in an ascitic form 
in mice to be used for in vivo Winn assay. 
 Cis-Diammindichloroplastinum (II) (CDDP ) 
was obtained from Nippon Kayaku Co, Ltd., 
Japan. Its solubility is 500 ,u g/ml. To admin-
istrate to animals, the drugs was diluted with 
sterile 0.9% NaCl solution at the desired con-
centrations and 0.5 ml was injected i.p into each 
mouse. 
 Carrageenan type IV was obtained from Sig-
ma Chemical Co. Thioglycolate medium was 
obtained from Difco Laboratories, Detroit. 
MI. 3H-TdR (specific activity 6.7 Ci/m mol ) 
was obtained from New England Nuclear, Bos-
ton, MA. 
2) Preparation of murine macrophages 
 C57BL/6 mice were given i.p injection of 
various doses of CDDP, and saline to controls. 
Peritoneal exudate cells (PEC) were harvested 
four days later by peritoneal lavage with ice-
cold RPMI. PEC were washed two times with 
PBS and suspened in RPMI 1640 supplemented 
with 10% FCS containing penicillin(100 U/ml), 
streptomycin (0.05 mg/ml). 
 After determination by viable and differenti-
al cell counts, macrophages were adjusted to 
1 X 106/ml and 0.1 ml (1 X 105) were dispensed 
into the flat-bottomed wells of a 96-well cul-
ture plate (Corning). After incubation at 37 °C 
for 90 minutes, nonadherent PEC were removed 
by repeated washing with PBS, and finally ap-
proximately 45% to 55% of the initialy added 
cells remained in cultured wells. The majority 
of these cells (>90%) morphologically resem-
bled macrophages. The compound at the CDDP 
dose of 4 mg /kg or less causes no apparent 
toxicity, since>95% harvested PEC were viable 
and about 50% of those cells were capable of 
adhering to plastic plate. 
3) Treatment of effector cells with carrageenan 
 For in vivo studies, all mice were treated with 
CDDP 4 mg/kg on Day-4 and some mice were 
given ip p injection of 1 mg carrageenan (1 mg 
/ml) on Day-3 and -1, respectively. PEC were 
harvested on Day-0, and tested in vitro for cy-
tostasis with an E : T ratio of 10 : 1. 
4) Assay for macrophage-mediated tumor cell 
cytostasis 
 The exponential phase EL-4 and Meth-A tu-
mor cells cultured in RPMI 1640 containing 10% 
FCS were washed twice with PBS, and resus-
pended in fresh RPMI 1640 containing 10 % 
FCS culture medium. 1 X 104 cells in 0.1 ml cul-
tured medium were added to culture wells con-
taining macrophages (1 X 105 in 0.1 ml) or to 
wells containing 0.1 ml of medium only for con-
trol. 
  Unless otherwise noted, culture plate were 
incubated at 37°C in a 5% CO2 and water-satu-
rated atmosphere for 48 hours. Cells in each 
wells were pulsed with 0.5 ,u Ci 3H-TdR for the 
final four hours and harvested with a semiauto-
matic multiple cell harvester (LABO SCIENCE 
CO LTD) to glass fiber. The amount of 3H-TdR 
incorported was determined in a liquid scintil-
lation counter (Aloka, LIQUID SCINTILLATION 
SYSTEM Model LSC-903). The mean cpm were 
obtained from triplicate cultures, and the re-
sults were presented as percentage cytostasis 
which was calculated by the following formula. 
     % Cytostasis = ( 1 - b- c                                a )
  Where "a" is cpm of cultures containing tar-
get cells only, "b" is cpm of cultures containing 
target cells and macrophages, and "c" is cpm 
of cultures containing macrophages only. 
 The results % cytostasis are representative 
of three separate experiments. 
5) In vivo effect of carrageenan on CDDP treat-
 ed tumor bearing mice 
 Group (A)-(D), each group consisting of 5 
C57BL/6 male mice 10 weeks old were treated 
with i.p injection of EL-4 tumor cells, CDDP, 
and carrageenan as follows. Group (A) : EL-4 
tumor cells only, Group (13): EL-4 tumor cells 
+carrageenan, Group (C): EL-4 tumor cells+ 
CDDP 4 mg/kg, Group (D): EL-4 tumor cells 
+CDDP 4 mg/kg+carrageenan. 
 Briefly, On Days -3 and -1 (B), (D) Groups 
were given i.p injection of carrageenan 1 mg 
permouse, On Day 0 all groups were treated 
with i.p injection of EL-4 tumor cells (2 X 106 
in 1 ml) which were maintained in ascitic form 
in C57BL/6 mice and on Day+1 (C)(D) Groups 
were given i.p injection of CDDP 4 mg /kg. 
The effect of carrageenan was expressed by the 
survival time (rate). 
6) In vivo tumor neutralization assay (Winn 
 assay)
  Each group consist of 5 to 6 BALB/Coy' mice 
irradiated with 400 rads one day before inocula-
tion. The effector cell suspension 0.1 ml (macro-
phage 5 X 107 /ml) was mixed with an equal 
volume of tumor cell suspension (Meth-A 1 X 
107/ml) and 0.2 ml of the cell mixture was 
inoculated s.c into the back of syngeneic BALB 
/C mouse. The results were evaluated by mea-
suring the long axis X short axis of the tumors. 
The group division was as follows: (A) inocu-
lated with Meth-A cells only. (B) inoculated 
with the mixture of Meth-A cells and thioglyco-
late treated macrophages. (C) inoculated with 
Meth-A cells and CDDP treated macrophages. 
(D) inoculated with the mixture of Meth-A 
cells and macrophages treated with CDDP and 
carrageenan. 
7) Flow cytometry 
  a) Propidium Iodide staining : For the analy-
sis of the cell cycle distribution of Meth-A cells, 
after exposed to CDDP (0.5 ,u g/ml) for 48 
hours, or cocultured with macrophages, the 
cells were fixed with 70% alcohol for at least 
overnight. Alcohol-fixed cell suspensions were 
rinsed and treated with RNase 1 mg/ml (Sigma, 
RNase type 1-A) at 37'C for 20 min. Rinsed 
again and stained with P.I solution (50 ,u g/ml) 
for two to three hours at 4°C. 
  b) Acridine Orange staining : For the analy-
sis of RNA contdnt of macrophages, control 
PEC or PEC treated with various doses of 
CDDP and OK-432 (1 KE/mouse) were puri-
fied by the adherence method. Adherence perito-
neal cells (APC) were fixed in ethanol : acetone 
(1 : 1 v /v ) mixture for at least overnight. 
Fixed cells were then stained by the two-step 
A.O staining method as described by Darzyn-
kiwicz.21) Brifely fixed single cell suspensions 
were adjusted to 1 X 106/ml. Aliquots of 0.2 ml 
of cell suspensions were mixed with 0.4 ml of 
ice-cold acid detergent (0.01% Triton, 0.08 N 
HCI, 0.15 N NaCl, 10-4 EDTA-Na) for 30 sec. 
The cells were then stained by addition of 1.2 
ml of A.O solution (concentration 10 ,u g/ml, 
diluted by phosphatecitrate buffer PH 6.0 ). 
After 5 minutes of interation the cells were 
measured in FACS with an argon laser (488nm). 
The red (>600nm) fluorescence, and light scat-
ter per cell were obtained for 5000 cells from 
each saple.
 c) Fluorescein isothiocyanate (FITC) stain-
ing 22) : For analysis of protein content. 70 
alcohol-fixed macrophages were stained with 
FITC 50 ,u g/ml (diluted by 0.5M NaHCO3 so-
dium bicarbonate PH 8.0) for 30 min at VC, 
and then measured in FACS with an excitation 
length of 488nm and absorption length of 530nm. 
 d) Supervital Rhodamine123 staining of 
mitochondria : Each sample of viable macro-
phages were stained with Rh123 10 u g/ml 
(dye dilutions were made in RPMI medium con-
taining 10% FCS) for 20 min at 37°C as describ-
ed by Darzynkiewicz.23) 
 e) Phagocytic activity of macrophages: Mac-
rophages (2 X 105 /ml) were incubated with 
fluorescent latex beads (1 X 107 /ml, DIA.1= 
1.73, a Polyscience, Inc, Warrington) for 90 min 
at 37°C, then the excess beads were discaded, 
rinsed and the macrophages were harvested by 
repeated pipetting with 0.2 % EDTA +0.02 % 
trypsin solution. Centrifugation and the pelets 
were resuspended with RPMI medium, and mea-
sured in FACS by counting 5000 cells. 
  Phagocytosis = cells phagocyte at least one bead                     t
otal cell counted
          RESULT 
1) Induction of tumor-cytostatic macrophages 
in vivo 
 Macrophages prepared from C57BL/6 mice 
treated with doses of CDDP ranging from 0.3 
to 4 mg/kg showed a dose-response cytostatic 
effect to both syngerneic EL-4 cells and alloge-
neic Meth-A cells. (Fig. 1) Although the magni-
tude of responses of allogeneic cells (% cytosta-
sis 52±12 to 61.3±9) was not so significant as 
syngerneic cells do (% cytostasis 78±15 to 83 
± 13). A dose of CDDP lesser than 0.3 mg/kg 
did not show any activation effect and the dose 
higher than 4 mg/kg showed the adverse toxic 
effect to macrophages. Therefore, we considered 
the 4 mg/kg was the optimal dose to activate 
the macrophages, and in the following experi-
ments mice were treated with a dose of 4 mg/ 
kg. Thioglycolate was reported as having no 
effect on macrophages activation, but in this 
study the thioglycolate treated macrophages 
showed somewhat higher cytostatic effect than 
untreated macrophages does. Macrophages from
Fig. 1. Dose-response effect of CDDP on the activation of macrophage as campared to the efect of OK-
      432 and thioglycolate. C57/BL6 mice weere treated with vsrious doses of CDDP, 3 % thiogly-
      colate 1 ml /mouse and OK-432 1 K.E/mouse. Macrophages were prepared 4 days later for 
      testing tumor cytostasis at an E : T ratio of 10 : 1.
                 Days after i.p injection of CDDP 4 mg/Kg 
Fig. 2. Persistance of activated macrophages following a single dose of CDDP. Macrophages were 
      prepared by the peritoneal lavage at various time intervals after treatment with CDDP 4 mg/
      kg. and tested for cytostasis at an E : T ratio of 10 : 1 for 48 hrs.
mice treated with immunostimulant agent 
OK-432 showed a significant cytostatic effect 
both to EL-4 and Meth-A cells. 
2) Persistance of activated macrophages 
 Fig. 2 demonstrated the time course of macro-
phages activated by CDDP. After a single bolus 
of CDDP 4 mg/kg macrophages were prepared 
at various time intervals, cytostatic effect was 
elevated as early as two days, appeared to be 
the maximal activated state four days later, 
and declined to the control state by 12 days. 
3) Inactivation of CDDP-activated macrophages 
with carrageenan 
 Effector cells which caused the cytostatic 
effect being investigated resembled to macro-
phages morphologically and in the ability to 
adhere to the plastic plate. In an attempt to 
further identify the cell type involved in the 
cytostatic reaction, PEC were treated with 
carrageenan which was known to abrogate 
macrophage activity. As shown in Tab. 1 mice 
treated with carrageenan on Day-3 and Day-1 
twice, significantly abrogate the cytostatic ef-
fect of the. PECs. These findings strongly sug-
Table 1. Effect of carrageenan on CDDP-treated 
        macrophage 
 Target Treatment of % PC 
   cell mice`' cytostasis 
  EL-4 CDDP 83.2±13.0' 
         CDDP+ carrageenan 35.5± 6.4 p<0.05 
 Meth-A CDDP 61.3± 9.2 N. S          CDDP+ carrageenan 46.5±60.3 
aAll mice were treated with CDDP 4 mg/kg on 
Day -4 and some mice were given i. p injection 
 of 1 mg carrageenan/mouse on Day -3 and -1, 
macrophages were harvested on Day 0, and test-
ed for cytostasis with an E : T ratio of 10 : 1. 
b Mean ± S. E 
 Determined by comparison between mice given 
injection with and without carrageenan. 
gest that CDDP acted mainly upon macrophages 
rather than other population of the PECs. 
4) Effect of culture supernatants of activated 
macrophages 
 Macrophages prepared from mice treated with 
CDDP for four days, were cultured in vitro for 
two days, supernatants were harvested, filtrat-
ed through a 0.45 ,u m Millipore filter and mix-
ed to EL-4 tumor cell cultures at various dilu-
tions. The inhibition of tumor cells was deter-
mined two days later by 3H-TdR incorporation. 
Fig. 3 shows that these supernatants inhibited 
the growth of tumor cells in a concentration-
dependant fashion.
            concentration of test supernatant ( % ) 
Fig. 3. Release of a cytostatic factor (s) by CDD 
       P-activated macrophages Macrophages 
      prepared from C 57 BL /6 mice treated 
      with i.p injection of CDDP 4 mg/kg and 
      saline for control were cultured 2 days.
      Supernatants were harvested and tested 
       for cytostasis of EL-4 cells at various con-
       centrations. Concentration of superna-
      tant are given on a logarithmic scale as 
      percent (V/V) of the medium. 
5) In vivo influence of carrageenan on the anti-
tumor effect of CDDP 
 Compared to tumor cells transplantation on-
ly group, (all mice died within 28 days) mice 
received CDDP anticancer drug showed a signi-
ficant therapeutic effect (survival rate of 50% 
at the time of 50 days). On the other hand, the 
therapeutic effect of CDDP was diminished 
when mice were pretreated with carrageenan on 
days-3 and -1 twice. (Fig. 4) 
6) Augmentation of the in vivo tumor neutral-
ization activity of macrophages treated with 
CDDP (Fig. 5) 
 Effector cells treated with CDDP significant-
ly inhibited the tumor growth within 15 days 
(P<0.01^-P<0.1). However, the inhibitory ef-
feet was almost abrogated by treating with 
carrageenan suggesting that CDDP-activated 
macrophages may be the main effector cell to 
inhibite the tumor growth. 
7) Cell cycle specificity of Meth-A cells expo-
sure to CDDP or cocultured with CDDP-act-
ivated macrophages 
 Fig. 6 shows the direct cytostatic effect of 
CDDP by concentrations ranging from 0.005 to 
15.625 ,u g/ml. The concentration of 0.625 ,u g 
/ml shows cytostatic effect similar to the ef-
fect caused by CDDP-activated macrophages 
(61.3±9.2%). Therefore, in the following Flow 
cytometry analysis, concentration of 0.5 u g/ 
ml was used in the direct CDDP cytostatic effect 
test. 
 Flow cytometry analysis using P.1 staining 
for DNA of Meth-A cells (Fig. 7) demonstrated 
that in contrast to CDDP exposure (D) which 
accumulated Meth-A cells in G2M phase, CDDP 
and OK-432 activated macrophages appeared 
to block in the G1 /S phase of the cycle. The 
percentage fraction of the cell cycle was analyz-
ed by the dot plot method (Tab. 2). 
8) Promotion of functional phagocytosis and 
changes of cellular contents of macrophages 
treated with CDDP and OK-432 
 Fig. 8 demonstrated the phagocytosis of flu-
orescent beads by macrophages (upper) and cell-
ular contents of protein, RNA, and mitochon-
dria contents were analysed by the relative 
peak channel numbers. Both functional pha-
gocytotic function and quantitative content 
changes were in dose-dependent fashion. 
        DISCUSSION 
 Cisplasitn (Cis-dichlorodiamminoplatinum 
(II ), CDDP) is a cordination of the platinum, 
it's antitumor activity was first proved by 
RoslNBi rz(. et a124) in 1969, and is a potent chem-
otherapeutic drug for the treatment of a vari-
ety of human tumors. 
 The mechanism by which CDDP kills tumor 
cells is thought to be derived from direct inter-
calating platinum into the double helix strain 
of the cellular DNA, and resulted in the inhibi-
tion of cell division.25) 
 The in vitro 48 hours continuous exposure 
test showed that effective cytostatic concentra-
Fig. 4. In vivo influence of carrageenan on the anticancer effect of CDDP. All C57BL/6 mice received 
       i.p injection of EL-4 cells on Day 0, some mice were treated with carrageenan on Days-3 and 
      -1 , and another mice were treated with CDDP on Day 1. The influence was evaluated by the 
       survival rate.
Fig. 5. Tumor neutralization assay (Winn assay) by macrophages. 
      The effector cell suspension 0.1 ml was mixed with an equal volume of tumor cell suspension 
      and 0.2 ml of the cell mixure was inoculated s. c into syngerneic BALB /C mouse irradiated 
      400 rads 5 days before the inoculation. Tumor size were evaluated by the product of major axis 
       X minor axis.
Fig. 6. Direct cytostatic effect of CDDP. 
      Tumor cells were exposured contineously to CDDP for 48 hrs and then tested for 3H-Tdr 
       incorporation.
Fig. 7. DNA histograms of Meth-A cells 
      (A) cocultured with CDDP-activated macrophages, (B) cocultured with OK-432 activated 
      macrophages, (C) control, (D) exposured to CDDP. for 48 hrs.
Table 2. FACS-sorted phase fraction of the Meth-A cells incubated 
       with CDDP direct and CDDP- activated macrophages
                          fraction of the cell cycle (%)
                      Gl S G2M 
Control 35.3 2.3d 30.7 1.7 26.3 0.6 
CDDP directa 25.3 0.6 37.3 1.2 37.3 0.6 
CDDP-macrophage b 59.0 1.0 20.3 2.1 20.7 1.2 
OK-432 macrophage 63.2 3.2 21.3 1.5 15.5 1.7 
a 5 X10 5 Meth -A cells were incubated with CDDP 0.5 ug/ml for 48 
 hrs. b 
mice were treated i.p with CDDP (4 mg/kg), macrophages were 
 prepared 4 days later and cocultured with Meth-A target cells at 
 an E : T ratio of 10 : 1 for 48 hrs. 
a mice were treated with OK-432 1 KE/mouse 4 days.  mean S.E
Fig. 8. Functional phagocytosis (upper) and Cellur contents (lower) changes of CDDP-activated 
      macrophages as compared to that of OK-432 activated macrophages. 
tion was at least 3000 ng/ml (Fig. 5). How- hours of administration and thus the amount 
ever other reports demonstrated that a large of CDDP retained in the body is low compared 
percentage of CDDP is excreted within two to that used in vitro studies. 26) Furthermore,
within three hours of administration about 90 
% of the CDDP administrated is protein 
bound. Evidence suggests that only free-CDDP 
is active, therefore the concentration of active 
drug in the circulation approachs only 100 to 
280 ng/ml two hours after an i.v bolus. 27 ) 
This is far lower than our in vitro studies. 
Thus, beside the direct cytotoxic effect of 
CDDP other mechanisms are possible. 
 One of these posibilities, we thought, was 
the host immuno-effector cell mediated anti-
tumor effect. The defense mechanism of 
animals consists of several types of immuno-
competent.cells. LICHTENSTEIN et a1i9) reported 
the enhancement of NK cytolytic activity of 
the peritoneal and spleen cells by treatment of 
i.p injection of CDDP. However, in the 
present experiment, macrophages apparently 
were the primary target of CDDP as regard to 
cytostatic effect, since we investigated the 
peritoneal adhesive cells which morphologically 
resemble to macrophages and the effect was 
significantly abolished by treatment with 
carrageenan (Tab. 1, Fig. 4, 5.) which is known 
to abrogate macrophages activity. 28) 
 The antitumor effect of macrophages exposed 
to CDDP in vivo could be explained by several 
methanisms. 
 First, the drug may potentiate antitumor 
immunity through the elimination of any im-
munosuppressor cell activity that appears in 
the tumor bearing host.29) 30) In this experiment 
model the CDDP-activated macrophages tested 
in vitro was prepared from normal mice, there-
fore this hypothesis is unlikely to be possible. 
 Another mechanism could be an indirect acti-
vation of macrophages by CDDP through the 
release of macrophage-activating f actor, a 
lymphokine by peritoneal lymphocytes.") How-
ever, other investigaters20) have demonstrated 
that unlike the case of X-irradiation, treat-
ment of lymphocyte with CDDP could not 
enhance the cytotoxic effect of monocyte. 
 A third mechanism of the toxic effect on 
tumor cells could be a transfer of CDDP 
from macrophages to tumors.15) 16) This hypo-
thesis was unlikely to be true, as was shown in 
Flow cytometry analysis of the target cell 
cycle (Fig. 7 ). CDDP act to the G2M part 
different from CDDP-activated macrophage
which block G1/S phase of the cell cycle. 
 This last mechanism: CDDP could directly 
activate macrophages. This hypothesis is sup-
ported by the facts that the behavior of CDDP-
activated macrophages resemble to that of OK-
432-activated macrophages which showed the 
enhancement of functional phagocytotic activi-
ty, enlargement of cell size, and the increase 
of cell elements, such as protein, RNA, and 
mitochondria. 
 The mechanism by which macrophages were 
activated with CDDP is not yet established. 
However, inhibition of macrophage's DNA syn-
thesis by some macrophage-activating agents 
were reported. Tiu.vrAD GE et al.32) demonstrated 
that M5076 cell line which in vitro displays 
many of the functional characteristics of an 
activated macrophages, when exposed to the 
macrophage activating agents, e. g LPS, TPA 
irreversibly induced cessation of cellular divi-
sion. NnoA,,To et al.33) reported the inhibition of 
DNA synthesis in Guinea pig's peritoneal exu-
date macrophages, by treatment with immuno-
adjuvants such as MDP and LPS. These obser-
vations enable us to suggest that the inhibition 
of DNA synthesis (by CDDP) may be something 
related to the activation of macrophages, but 
this posibility awaits conformation. 
 Macrophages from mice treated with CDDP, 
doses ranged from 0.3-4 mg /kg, showed a 
dose-dependent cytostatic effect to both EL-4 
and Meth-A cells, the dose was almost coinci-
dent to that used in the clinical patients. On 
the other hand, the time interval required to 
activate macrophages was reported to be 24 
hours for Adriamycin.15) In the case of CDDP 
i.p injection, the exudate cells appeared in early 
phase is prominantly neutrophil and lymphocyte, 
and it is reasonable to explain that it takes 
times to activate the macrophages (Fig. 2). 
 Macrophages activated by Bisanthrene per-
sists for f our weeks, 34) While CDDP-activated 
macrophages showed relatively short persis-
tence, four days to reach the peak and declined 
to base line by 12 days (Fig. 2). This fact was 
well coincident to the Winn assay (Fig. 5) which 
the CDDP-activated macrophages showed a sig-
nificant antitumor effect within 15 days. 
 It was reported that the physical cell contact 
is necessary to induce the inhibition of tumor
cell proliferation,35) however, other reporters 
described that the inhibition was due to the 
soluble factors released by macrophages.36) 37) 
The difference may be due to the agents which 
activate the macrophages. In this study, we 
demonstrated that after 48 hours incubation 
the supernatant of CDDP-activated macropha-
ges was active for the inhibition of tumor cell 
proliferation, suggesting that cell-cell contact 
was unnecessary for cytostasis. 
 From the results described we conclude that 
in vivo, macrophages are activated by CDDP 
during a four to seven days duration to enlarge 
the cell size and change the cell elements, ulti-
mately resulted in the resealing of soluble anti-
tumor factors. 
 For the further investigation, Flow cytomet-
ry techniques were employed to analyse the 
changes of effector cells and kinectis of target 
cells. PROSSER et al.38) have reported that using 
radiolabled uridine and leucine incorporation 
method in the two murine macrophages cell 
lines of PU5-1.8 and J774.1, when treated with 
BCG, RNA and protein synthesis is pronounced 
in spite of decreased DNA synthesis. HAMILTON 
et al.39) demonstrated the enhanced synthesis 
of a series of at least six polypeptides of 85, 
80, 75, 65, 57 and 38 KD by treatment of mur-
ine peritoneal macrophages with LPS. In the 
present study, Flow cytometry analysis using 
A.O and FITC staining methods we showed the 
increase of RNA and protein contents of the 
CDDP or OK-432 activated macrophages (Fig. 
8). In contrast to the dose-dependent increase 
of protein the RNA increase was dose-indepen-
dent. Supervital staining of mitochondria was 
also analysed. The data we obtained was well 
coincide with that described by D \nzYNKirwicz23 ) 
who showed an increase of mitochondrial up-
take of Rh123 during lymphocyte stimulation 
by PHA. 
 Enhancement phagocytotic activity was an-
other functional change accompanied by acti-
vated macrophages. 17) By means of latex beads 
phagocytosis analysed by Flow cytometry.'io ) 
CDDP dose-dependent effect to functional pha-
gocytotic activity was shown (Fig. 8). Suggest-
ing not only the qualitative cell elements but 
also the functional activity changes occured 
during the activating of macrophages by CDDP.
  Finally, Flow cytometry using quantitative 
P.1 staining for DNA can distinguish target 
(Meth-A cell) from effector cells, because the 
DNA contents were different (P.1 staining fail-
ed to distinguish the macrophages from EL-4 
cells). Using this type of analysis, we have been 
able to demonstrate that in contrast to CDDP 
exposure, which resulted in the G2M accumula-
tion of the Meth-A cells, CDDP-activated mac-
rophages like OK-432 macrophages to have a 
different influence which block the cells in the 
Gi/S phase. This difference of inhibitory mech-
anism suggest that the contamination of CDDP 
or transport of CDDP by macrophage to tumor 
cells were unlikely to be responsible for the tu-
mor cell inhibition. HASKILL et al. 16) have report-
ed the accumulation of target cells at G2M 
fraction by ADR, they conclude that drug reten-
tion may be the prominant effector mechanism 
involved in the ADR-activated macrophages 
phenomenon. 
  The immunopotentiating effects of antican-
cer drugs has been reported, although mecha-
nisms were different. In this study, we confirm-
ed the enhancing effect of CDDP on macropha-
ges. This is a characteristics of the possibility 
for the direct intracavity admission of chemo-
therapy for patients with abdominal or pleural 
malignant effusions which frequently contain 
significant numbers of macrophages. 
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